4IMAI Y, CHIKAYAMA T, NAKAZAWA M, et al. Usefulness of miriplatin as an antieaneer agent for transcatheter arterial chemo- embolization in patients with unresectable hepatocellular carcino- rna[J]. J Gastroenterol, 2012,47(2) : 179 -186.
5KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) a- gainst a slowly-growing rat hepatictumor after intra-hepatic arterial administration [ J]. Biol Pharm Bull,2000, 23 (3) : 344 - 348.
6HANADA M, BABA A, TSUTSUMISHITA Y, et al. Intra-he- patic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted innude rats [ J].. Cancer Sci, 2009, 100 (1) : 189 -194.
7HANADA M, BABA A; TSUTSUMISHITA Y, et al. Intra-he- patic arterial administration with miriplatin suspendedin an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive ap- optosis [ J ]. Cancer Chemother Pharmacol, 2009, 64 (3) : 473 - 483.
8FUJIYAMA S, SHIBATA J, MAEDA S, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in pa- tients with hepatocellular carcinomarefractory to cisplatin/lipiodol [J]. Br J Cancer, 2003, 89(9) : 1614 -1619.
9OKUSAKA T, OKADA S, NAKANISHI T, et al. Phase II trial of intra-arterial chemotherapy using a novellipophilic platinum de- rivative ( SM-11355 ) in patients with hepatocellular carcinoma [ J ]. Invesi New Drugs, 2004, 22 (2) : 169 - 176.
10OKABE K, BEPPU T, HARAOKA K,et al. Safety and short- term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carci- noma [ J ]. Anticancer Res, 2011,31 ( 9 ) : 2983 - 2988.
